Advanced Cardiac MRI Identifies Early Signs of Transthyretin Amyloidosis

Why It Matters

Detecting ATTR‑CA before extensive infiltration enables clinicians to start disease‑modifying therapies sooner, potentially extending survival and reducing misdiagnosis with hypertrophic phenocopies.

Key Takeaways

• CMR identifies basal‑inferolateral LGE pattern in low‑burden ATTR‑CA
• Global extracellular volume and native T1 rise even with minimal amyloid load
• AUC for LGE reaches 0.99, outperforming strain‑based diagnostics
• Low‑burden patients show near‑normal wall thickness and better survival
• Early CMR detection may prompt timely tafamidis or gene‑silencing therapy

Pulse Analysis

Transthyretin cardiac amyloidosis has moved from a rare curiosity to a growing concern among older adults, yet its insidious onset often masquerades as hypertensive heart disease or hypertrophic cardiomyopathy. Conventional echocardiography and strain imaging typically capture structural changes only after substantial amyloid deposition, leaving a diagnostic blind spot. Cardiac magnetic resonance, with its ability to map tissue composition, offers a solution by quantifying extracellular volume and native T1 values, biomarkers that rise well before overt wall thickening becomes apparent. This shift toward tissue‑focused imaging aligns with a broader trend in cardiology: leveraging quantitative MRI to uncover subclinical disease.

The recent European Heart Journal Imaging study leveraged a cohort of 83 confirmed ATTR‑CA patients to define a distinctive basal‑inferolateral late gadolinium enhancement signature in low‑burden cases. By stratifying patients using an ECV threshold of 43%, researchers demonstrated that even minimal amyloid infiltration produces measurable changes in global ECV, native T1, and LGE extent. Diagnostic performance metrics were striking—global LGE achieved an area‑under‑the‑curve of 0.99, eclipsing traditional strain‑based approaches. Moreover, the imaging phenotype differentiated ATTR‑CA from hypertrophic phenocopies, which either lack focal fibrosis or display an anteroseptal pattern, thereby reducing the risk of therapeutic misdirection.

Clinically, the ability to flag ATTR‑CA at an early stage reshapes treatment pathways. Patients identified with low‑burden disease can be evaluated for tafamidis, patisiran, or inotersen—agents shown to slow progression when administered before severe myocardial stiffening. Early intervention not only improves survival odds but also curtails the economic burden of advanced heart failure management. While the study’s single‑center design limits generalizability, it paves the way for multicenter trials and potentially for screening protocols in high‑risk populations, such as elderly patients with unexplained left‑ventricular hypertrophy. As CMR technology becomes more accessible, its role in the diagnostic algorithm for amyloid cardiomyopathy is poised to expand, offering a pragmatic bridge between early detection and timely therapy.